FDA Grants Approval to Atezolizumab for Alveolar Soft Part Sarcoma

On December 9, 2022, the U.S Food and Drug Administration (FDA) approved atezolizumab for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma.

For more information read the FDA announcement.

Posted 12/12/2022